BIOPROCESSING USING BIORECEPTOR FERROFLUIDS AND HGMS

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: N/A
Agency Tracking Number: 16629
Amount: $383,836.00
Phase: Phase II
Program: SBIR
Awards Year: 1992
Solicitation Year: N/A
Solicitation Topic Code: N/A
Solicitation Number: N/A
Small Business Information
Immunicon Corp.
1310 Masons Mill Ii, Huntingdon Valley, PA, 19006
DUNS: N/A
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 Liberti, Paul A
 Principal Investigator
 (215) 938-0100
Business Contact
 1 R43 GM45658-01A1
Phone: () -
Research Institution
N/A
Abstract
THE LONG-TERM OBJECTIVE IS TO DEVELOP A NEW TECHNOLOGY FOR INDUSTRY SCALE AFFINITY SEPARATIONS EMPLOYING PROPRIETARY BIO- RECEPTOR FERROFLUIDS (BR-FF) IN COMBINATION WITH EXISTING HIGH GRADIENT MAGNETIC SEPARATORS (HGMS) AND IMPROVED SYSTEMS CURRENTLY BEING DEVELOPED. BR-FF ARE BEING USED SUCCESSFULLY FOR DOING IMMUNOASSAYS AND TOGETHER THEY REPRESENT A SIGNIFICANT STEP FORWARD IN THE FIELD OFFERING NUMEROUS ADVANTAGES OVER PRIOR SYSTEMS. THE SPECIFIC AIMS OF THIS PROJECT ARE TO DETERMINE IF BR-FF AS CURRENTLY SYNTHESIZED OR AS SYNTHESIZED BY RELATIVELY STRAIGHTFORWARD MODIFICATION CAN WITHSTAND THE RIGORS OF DESORPTION (LOW PH, DENATURANTS, CHAOTROPIC IONS) AND RECYCLING. AFFINITY SEPARATIONS CURRENTLY PLAY A MINOR ROLE IN BIOPROCESSING, IN PART BECAUSE OF COST AND THE NATURE OF AFFINITY SUPPORTS (PARTICLES OR MEMBRANES) WHICH ARE CONSTRAINED TO BATCH MODE AND ULTRA-CLEAN SOLUTIONS. BR- FF AND HGMS OFFERS THE POTENTIAL FOR CONTINUOUS AFFINITY SEPARATION WHICH CAN FUNCTION IN THE PRESENCE OF MAJOR SOLUTION CONTAMINANTS INCLUDING SOLIDS; THUS A NEW BIOPROCESSING TECHNOLOGY WHICH ALSO REQUIRES SIGNIFICANTLY FEWER PROCESSING STEPS POSSIBLE.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government